<?xml version="1.0" encoding="UTF-8"?>
<p>HBV-infected pregnant women between 20 and 35 years old were enrolled from January 2009 to February 2012 at the Chengyang People's Hospital of Qingdao. Telbivudine was administrated from 12 weeks after gestation to the 12th postpartum week. All patients had HBV DNA levels great than 10
 <sup>7</sup>â€ŠIU/mL. Coinfection with hepatitis C virus, hepatitis D virus, hepatitis A virus, hepatitis E virus, human immunodeficiency virus, concurrently being confirmed with other liver diseases (drug-induced hepatitis, nonalcoholic steatohepatitis, autoimmune hepatitis, ntrahepatic cholestasis of pregnancy, etc.) or having signs of fetal dysplasia were excluded. Informed consents were received from all the patients before enrollment.
</p>
